BLAINJECTIONSOLUTION1 Generic Approved
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ENOBY (denosumab-qbde) by Hikma is rank ligand blocking activity [moa]. Approved for rank ligand inhibitor [epc]. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENOBY (denosumab-qbde) is a monoclonal antibody that blocks RANK ligand to inhibit osteoclast formation and bone resorption. It is a biosimilar follow-on to Amgen's reference denosumab products (Prolia and Xgeva), indicated for bone loss and skeletal complications. The drug is administered via subcutaneous or intravenous injection depending on indication.
Launch
Early-stage launch with moderate competitive pressure (30/100); team size will depend on Hikma's commercial infrastructure and market penetration strategy.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ENOBY offers exposure to biosimilar launch and payer/formulary strategy, but limited clinical development opportunity. Success depends on strong commercial execution, negotiation skills, and ability to compete in a crowded market with modest differentiation.
Brand ManagerField Sales Representative
Worked on ENOBY at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.